Document is current
Any future updates will be listed below
-
Authors
Antfolk, Daniel https://orcid.org/0000-0001-9163-3740
Ming, Qianqian https://orcid.org/0000-0003-0296-7859
Manturova, Anna https://orcid.org/0000-0002-6336-9943
Goebel, Erich J.
Thompson, Thomas B.
Luca, Vincent C. https://orcid.org/0000-0001-9427-5520
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM133482, R35GM134923, R35GM134923)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA076292)
- License Information
-
More Information
Article History
Received: 3 October 2024
Accepted: 30 May 2025
First Online: 1 July 2025
Competing interests
: V.C.L. is a consultant on unrelated projects for Cellestia Biotech, Remunix, and Curie. Bio. T.B.T. is a consultant/advisor for Keros Therapeutics and Oviva Therapeutics. The remaining authors have no competing interests.
